Navigation Links
Combination therapy shows potent tumor growth inhibition in preclinical studies
Date:11/13/2011

SAN FRANCISCO Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

"These preclinical findings suggest that combining REGN910 (SAR307746) and aflibercept in the clinic could be an attractive approach for future clinical research," said Alshad S. Lalani, Ph.D., director of strategic oncology development at Regeneron Pharmaceuticals Inc. in Tarrytown, N.Y. "The rationale is that inhibition of tumor angiogenesis by combining antiangiogenesis treatments could translate into more potent and durable antitumor responses than those observed with single-agent therapy."

In this preclinical mouse study, researchers from Regeneron and BC Cancer Agency in Vancouver, British Columbia, Canada, monitored how REGN910 and aflibercept blocked vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), which are critical growth factors for tumor angiogenesis, or blood vessel formation.

REGN910 is a fully human monoclonal antibody discovered using Regeneron VelocImmune antibody technology that binds and inhibits Ang2. Aflibercept is a fully human fusion protein that binds all forms of VEGF-A, as well as VEGF-B and placental growth factor. REGN910 and aflibercept are being developed by Regeneron and Sanofi.

In addition, researchers performed tissue analyses to monitor the number of tumor blood vessels, tumor hypoxia (oxygen deprivation), tumor cell death and tumor perfusion.

"When used alone in animal studies, both REGN910 and aflibercept blocked tumor angiogenesis and growth; however, the combination of the two led to increased tumor hypoxia and consequently to the death of a large percentage of the tumor cells," Lalani said. "Consistent with its ability to promote rapid and widespread tumor cell death in histology, the combination treatment inhibited tumor growth to a significantly greater extent than the single agents in multiple tumor models colorectal, mammary and prostate. In particular, it caused dramatic tumor regression in the colorectal tumor models. Importantly, no visible evidence of toxicities or enhanced body weight loss was observed following the combination treatment."

In ongoing animal studies, Lalani and colleagues are studying the reasons behind the results with the combined therapy. They are also investigating biomarkers that will allow them to monitor the combination therapy treatment effect and/or to identify which tumors are most likely to respond to treatment.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Manchesters first step to perfect drug combinations
2. Combination HPV diagnostic test for head and neck cancer outperformed other tests
3. Novel drug combination offers therapeutic promise for hard-to-treat cancers
4. The machinery for recombination is part of the chromosome structure
5. Promising developments in vaccine research, development of a vaginal gel and PrEP lead to calls for a combination of biomedical and non biomedical approaches to HIV prevention policy
6. Unique gene combinations control tropical maize response to day lengths
7. A drug combination extends survival in refractory lung cancer patients
8. Microbubble-delivered combination therapy eradicates prostate cancer in vivo
9. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
10. Killing drug-resistant melanoma requires combination therapy
11. Combination therapy reduced HER2-positive breast cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... ... June 22, 2017 , ... RURO, Inc., a leading ... 6.5, a content-packed update to the Limfinity® framework. , LimitLIS® and other RURO ... diverse base of customers among labs and other businesses. Limfinity® 6.5 adds new ...
(Date:6/20/2017)... Pa. , June 20, 2017  Kibow Biotech ... pleased to announce the issuance of a new patent ... or hyperuricemia by the U.S. Patent and Trademark Office ... a winner of the Buzz of Bio award in ... is akin to developing non-drug approaches to chronic disease. ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... clinical development reported today that it is launching two new additions of its ... be demonstrating new capabilities at the DIA 2017 Annual Meeting in Chicago, IL, ...
(Date:6/16/2017)... ... June 16, 2017 , ... CTNext , Connecticut’s go-to resource ... held at The LOFT at Chelsea Piers in Stamford. , Nine finalists, all of ... of judges for an opportunity to secure $10,000 awards to help support business growth. ...
Breaking Biology Technology: